We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-11.59%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.6B
AUM Growth
-$3.29B
Cap. Flow
-$1.2B
Cap. Flow %
-8.83%
Top 10 Hldgs %
51.07%
Holding
116
New
14
Increased
50
Reduced
18
Closed
20

Top Buys

Rank Stock Value
1
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
+$538M
2
RHT
Red Hat Inc
RHT
+$426M
3
AABA
Altaba Inc
AABA
+$393M
4
CI icon
Cigna
CI
+$220M
5
EQIX icon
Equinix
EQIX
+$196M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$1.51B
2
ESRX
Express Scripts Holding Company
ESRX
+$1.13B
3
COL
Rockwell Collins
COL
+$584M
4
DELL icon
Dell
DELL
+$430M
5
EVHC
Envision Healthcare Holdings Inc
EVHC
+$257M

Sector Composition

Rank Sector Weight
1 Communication Services 23.71%
2 Healthcare 20.51%
3 Technology 18.84%
4 Industrials 7.34%
5 Consumer Discretionary 4.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILPT
76
Industrial Logistics Properties Trust
ILPT
$554M
$12M 0.09%
+610,545
New +$13M
APTX
77
DELISTED
Aptinyx Inc. Common Stock
APTX
$11.1M 0.08%
670,000
– –
TECX
78
Tectonic Therapeutic
TECX
$736M
$10.8M 0.08%
54,167
+15,417
+40% +$4.7M
ZEAL
79
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$10.4M 0.08%
900,000
– –
PRNB
80
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$9.59M 0.07%
350,000
+225,000
+180% +$5.8M
LRMR icon
81
Larimar Therapeutics
LRMR
$434M
$8.79M 0.06%
147,917
+12,500
+9% +$1.23M
MLNX
82
DELISTED
Mellanox Technologies, Ltd.
MLNX
$8.78M 0.06%
+95,000
New +$8.07M
VYGR icon
83
Voyager Therapeutics
VYGR
$209M
$8.55M 0.06%
909,158
– –
ASMB icon
84
Assembly Biosciences
ASMB
$700M
$7.92M 0.06%
29,167
+4,167
+17% +$1.21M
VOYA icon
85
Voya Financial
VOYA
$8.86B
$7.43M 0.05%
185,000
– –
THOR
86
DELISTED
Synthorx, Inc. Common Stock
THOR
$6.71M 0.05%
+386,092
New +$5.6M
TBIO
87
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$3.75M 0.03%
500,000
+50,000
+11% +$366K
GCVRZ
88
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.28M 0.02%
6,827,805
– –
BLCM
89
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.92M 0.02%
100,000
-113,663
-53% -$5.04M
CRNX icon
90
Crinetics Pharmaceuticals
CRNX
$8.99B
$2.86M 0.02%
95,365
-46,450
-33% -$1.31M
ITCI
91
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.85M 0.02%
250,000
– –
AVA icon
92
Avista
AVA
$3.15B
$2.67M 0.02%
62,900
-1,407,100
-96% -$69.7M
PFNX
93
DELISTED
Pfenex Inc.
PFNX
$1.91M 0.01%
600,000
– –
TYME
94
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$1.11M 0.01%
300,857
-105,000
-26% -$295K
VTAK icon
95
Catheter Precision
VTAK
$755K
– –
-1
Closed -$2.36M
CHRS icon
96
Coherus Oncology
CHRS
$219M
– –
-700,000
Closed -$11.6M
KALV
97
DELISTED
KalVista Pharmaceuticals
KALV
– –
-200,000
Closed -$4.42M
NTLA icon
98
Intellia Therapeutics
NTLA
$1.8B
– –
-550,000
Closed -$15.7M
PBYI icon
99
Puma Biotechnology
PBYI
$477M
– –
-410,000
Closed -$18.8M
SLDB icon
100
Solid Biosciences
SLDB
$997M
– –
-19,667
Closed -$13.9M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2018 Portfolio in Review

As of Q4 2018, Thomas Steyer held 116 positions worth $13.6B, down 19% from $16.9B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Thomas Steyer withdrew a net $1.2B in Q4 2018, closing 20 positions and reducing 18 holdings. Its most notable exit was Aetna Inc, an estimated $1.51B position sold in full.

By sector, the portfolio is most concentrated in Communication Services at 24% of assets, up from 13% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Thomas Steyer opened a new position in Red Hat Inc worth $472M.

  • Thomas Steyer's largest Q4 2018 buy was Red Hat Inc: 2,685,000 shares worth $472M.
  • Thomas Steyer added most to Twenty-First Century Fox, Inc. Class A in Q4 2018, an estimated $538M increase.
  • Thomas Steyer's biggest Q4 2018 reduction was Dell, cutting an estimated $430M.
  • Thomas Steyer fully exited Aetna Inc in Q4 2018, selling an estimated $1.51B.
  • Thomas Steyer's ten largest holdings make up 51% of its $13.6B portfolio in Q4 2018.
  • Thomas Steyer opened 14 new positions and closed 20 in Q4 2018.
  • Thomas Steyer's portfolio value fell 19% quarter-over-quarter to $13.6B.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.